PoNS Therapy Revenue
Medical Equipment Manufacturing • 
Newtown Township, Pennsylvania, United States • 21-50 Employees
PoNS Therapy revenue & valuation
| Annual revenue | $295,000 |
| Revenue per employee | $9,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Medical Equipment Manufacturing industry and current estimated revenues | $944,000 |
| Total funding | $500,000,000 |
Key Contacts at PoNS Therapy
Mikir Bodalia
Director Of Quality Assurance And Hipaa Compliance Officer
Gerry Huber
Director, Manufacturing, Supply Chain & Logistics
Michael Milloy
Managing Director Canada
Nicole Strachan
Associate Director - Clinical Development And Data Analysis
David Borquez
Director Of It, Business Systems Architect
Sherrie Perkins
Independent Director
Michelle Carlisi
Director Of Marketing, North America
Janet Holland
Director Of Sales Development
Steve Mendez
Director Of Product Engineering
Whitney Patrickson
Director Of Physical Therpay
Company overview
| Headquarters | 642 Newtown Yardley Road, Suite 100, Newtown, Pennsylvania 18940, US |
| Phone number | +18775640008 |
| Websites | |
| SIC | 384 |
| Employees | 21-50 |
| Socials |
PoNS Therapy Email Formats
PoNS Therapy uses 3 email formats. The most common is {first initial}{last name} (e.g., jdoe@heliusmedical.com), used 76.2% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@heliusmedical.com | 76.2% |
{first name}{last name} | johndoe@heliusmedical.com | 14.3% |
{last name}{last name} | doedoe@heliusmedical.com | 9.5% |
About PoNS Therapy
PoNS®, short for Portable Neuromodulation Stimulator, is an innovative medical device. It is inclusive of a controller and mouthpiece, that delivers mild stimulation to the surface of the tongue. This stimulation triggers a flow of neural impulses to the brain structures that control balance and gait. PoNS is meant to be used in conjunction with supervised therapeutic activity, referred to as, PoNS Therapy®. Use of the device while engaging in movement and coordination tasks promotes neuromodulation, and consequently, neuroplasticity, activating brain pathways for a lasting improvement in balance and/or gait. PoNS is authorized in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. PoNS is authorized in Canada for three indications: (i) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used in conjunction with physical therapy; and (ii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy; and (iii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from stroke, to be used in conjunction with physical therapy. PoNS is authorized in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
PoNS Therapy has 15 employees across 8 departments.
Departments
Number of employees
United Kingdom
Colombia
Germany
Frequently asked questions
4.8
40,000 users
